Celcuity Reports Q1 Results, Advances Gedatolisib Pipeline with New Formulation & Expanded Trials

summarizeSummary

Celcuity reported increased Q1 losses driven by commercialization efforts, while reiterating positive clinical trial results and FDA Priority Review for gedatolisib. The company also announced an expanded Phase 3 trial and a new subcutaneous drug formulation, supported by substantial capital resources.

check_boxKey Events · Earnings and Guidance · CELC

• Q1 Financial Performance

  Net loss increased to $52.8 million in Q1 2026 from $37.0 million in Q1 2025, driven by a 174% increase in selling, general, and administrative expenses to $17.4 million, and an 11% rise in R&D expenses to $33.1 million, reflecting commercialization preparations.

• Liquidity and Capital Resources

  The company holds $387.1 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing a liquidity runway of at least one year. Its ATM program was increased to $400 million in January 2026, offering substantial future capital raising capacity.

• Gedatolisib Clinical Progress

  Reiterated positive topline results from the VIKTORIA-1 Phase 3 trial (PIK3CA MT cohort) and confirmed FDA Priority Review for gedatolisib with a PDUFA goal date of July 17, 2026.

• Expanded VIKTORIA-2 Phase 3 Trial

  The VIKTORIA-2 Phase 3 trial design was amended to include endocrine-sensitive patients, expanding the potential market for gedatolisib, with topline data expected by end of 2028 and 2030.

auto_awesomeAnalysis · CELC · Industrial Applications And Services

Celcuity Inc. reported a net loss of $52.8 million for Q1 2026, an increase from $37.0 million in Q1 2025, primarily due to a significant 174% rise in selling, general, and administrative expenses as the company scales up for potential commercialization of gedatolisib. Research and development expenses also increased by 11%. The company maintains a liquidity runway of at least one year with $387.1 million in cash and investments. Operationally, the company reiterated positive topline results from the VIKTORIA-1 Phase 3 trial (PIK3CA MT cohort) and confirmed the FDA's Priority Review for gedatolisib with a PDUFA date of July 17, 2026. Additionally, Celcuity announced an expanded design for its VIKTORIA-2 Phase 3 trial and filed a patent application for a new subcutaneous formulation of gedatolisib, aiming to enhance patient convenience and broaden future indications. These developments, alongside an increased ATM program capacity of $400 million, underscore the company's aggressive pipeline advancement and capital strategy as it approaches potential market entry.